Thank you very much, Mr. Chair.
Thank you for being here, witnesses.
As my first comment, someone mentioned the loss of the intellectual properties. As far as I'm concerned, that's probably the most important thing here. If you look back at the Avro Arrow case, we suffered for 50 years because of that decision.
When we're talking about MDA, we were told by the CEO the other day that it is the jewel in the crown. One problem we have is that there's nothing else that's even close as far as we're concerned. We're talking about Canadarm, we're talking about Dextre. If you ask Canadians about our claim to fame in the aerospace industry, they would probably name those two things.
By selling our intellectual property to the American company--there's nobody else in the wings--what are the consequences? Someone was saying that it's zero to 10 years to develop this from scratch. There's not a second company that's 50% of MDA that can take up the fight, if you will, for Canada.
What does that mean for Canada over the next 10, 20, or 30 years?